Professional Documents
Culture Documents
Syndrome
Steven R. Bruhl MD, MS
3rd Year Cardiology Fellow
Internal Medicine Didactics
July 14, 2010
Goals and Objectives
Discuss the definition & pathophysiology of
ACS
Recognize the clinical features of low,
intermediate and high risk ACS
Be able to identify and treat patients
appropriate for a conservative or invasive
strategy
Discuss new and controversial
pharmacological treatments
Gold Standard for Treatment of ACS
http://circ.ahajournals.org/cgi/content/full/102/10/1193
Algorithm for evaluation and management of patients suspected of having ACS.
Anderson JL, et al. J Am Coll Cardiol 2007;50:e1–e157, Figure 2.
ACS Overview
Overview of ACS
Assessment of “Likelihood of ACS”
Early Risk Stratification
Invasive vs Conservative Strategy
Pharmacotherapy
Long-term Therapy/Secondary Prevention
Scope of the Problem
5 million ER visits nationwide for CP
800,000 experience an MI each year
213,000 die from their event
½ of those die before reaching the ER
Acute Coronary
Syndromes*
UA/NSTEMI† STEMI
*Primary and secondary diagnoses. †About 0.57 million NSTEMI and 0.67 million UA.
Heart Disease and Stroke Statistics – 2007 Update. Circulation 2007; 115:69–171.
Acute Coronary Syndrome (ACS)
[----UA---------NSTEMI----------STEMI----]
Pathophysiology of Stable Angina and ACS
Pathophysiology ACS
Decreased O2 Supply
Asymptomatic
•Flow- limiting stenosis
•Anemia
•Plaque rupture/clot
Angina
Increased O2 Demand
O2 supply/demand mismatch→Ischemia
Myocardial ischemia→necrosis
Pathophysiology of ACS
Evolution of Coronary Thrombosis
Unstable
NSTEMI STEMI
Angina
Non-occlusive
thrombus Complete thrombus
Non occlusive sufficient to cause occlusion
thrombus tissue damage & mild
myocardial necrosis ST elevations on
Non specific ECG or new LBBB
ECG ST depression +/-
T wave inversion on Elevated cardiac
Normal cardiac ECG enzymes
enzymes
Elevated cardiac More severe
enzymes symptoms
STEMI
Name 3 situations in which you cannot
diagnose STEMI
STEMI
Name 3 situations in which you cannot
diagnose STEMI
Paced Rhythm
Cardiac Catheterization
Name the only 3 situations that demand
emergent cardiac catheterization.
Cardiac Catheterization
Name the only 3 situations that demand
emergent cardiac catheterization.
At least 2 of the
following
History ( angina or angina
equivalent)
Acute ischemic ECG changes
Typical rise and fall of cardiac
markers
Absence of another identifiable
etiology
Initial Evaluation and management
of Non ST-elevation ACS
Initial Evaluation and Management
Shapiro BP, Jaffe AS. Cardiac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo Clinic Cardiology: Concise Textbook. 3 rd ed. Rochester, MN:
Mayo Clinic Scientific Press and New York: Informa Healthcare USA, 2007:773–80.
Anderson JL, et al. J Am Coll Cardiol 2007;50:e1–e157, Figure 5.
Risk Stratification by Troponin
8 7.5 %
7
6.0 %
Mortality at 42 Days
6
5
4 3.4 % 3.7 %
3
2
1.7 %
1.0 %
1
831 174 148 134 50 67
0
0 to <0.4 0.4 to <1.0 1.0 to <2.0 2.0 to <5.0 5.0 to <9.0 9.0
Conservative
Unstable angina/NSTEMI cardiac
care
Evaluate for conservative vs. invasive strategy
based upon:
Likelihood of actual ACS
Risk stratification by TIMI risk score
Low High
Intermediate
TIMI Risk Score
Predicts risk of death, new/recurrent MI, need for urgent revascularization within 14 days
TIMI Risk Score
Definitive/Possible ACS
Initiate ASA, BB, Nitrates,
Anticoagulants, Telemetry
Remains Stable
Recurrent Signs/Symptoms ↓
Coronary angiography Heart failure Assess EF and/or Stress Testing
(24-48 hours) Arrhythmias ↓
EF<40% OR Positive stress
Go to Angiography
Specifics of Early Hospital Care
Anti-Ischemic Therapy
Anti-Platelet Therapy
Anticoagulant Therapy
Early Hospital Care
Anti-Ischemic Therapy
Class I
Bed/Chair rest and Telemetry
Oxygen (maintain saturation >90%)
Nitrates (SLx3 Oral/topical. IV for ongoing iscemia, heart
failure, hypertension)
Oral B-blockers in First 24-hours if no contraindications.
(IV B-blockers class IIa indication)
Non-dihydropyridine Ca-channel blockers for those with
contraindication fo B-blockers
ACE inhibitors in first 24-hours for heart failure or
EF<40% (Class IIa for all other pts) (ARBs for those
intolerant)
Statins
Early Hospital Care
Anti-Ischemic Therapy
Class III
Nitrates if BP<90 mmHg or RV infarction
Nitrates within 24-hrs of Sildenafil or 48 hrs of Tadalafil
Immediate release dihydropyradine Ca-blockers in the
absence of B-Blocker therapy
IV ACE-inhibitors
IV B-blockers in patients with acute HF, Low output state
or cardiogenic shock, PR interval >0.24 sec, 2nd or 3rd
degree heart block, active asthma, or reactive airway
disease
NSAIDS and Cox-2 inhibitors
Early Hospital Care
Anti-Platelet Therapy
Class I
Aspirin (162-325 mg), non enteric coated
Clopidogrel for those with Aspirin
allergy/intolerance (300-600 mg load and 75 mg/d)
GI prophylaxis if a Hx of GI bleed
Bivalarudin
Fondaparinux
MIRACL Trial
Inclusion Criteria
3086 patients with Non ST ACS
Total cholesterol <270 mg/dl
No planned PCI
Atorvastatin
10
1.5
Placebo
1
Atorvastatin
0.5
Relative risk = 0.49
P = .04
95% CI 0.24-0.98
0
0 4 8 12 16
Time Since Randomization (weeks)
Waters DD, et al. Circulation. 2002;106:1690-1695. S24
PROVE-IT Trial
All-Cause Death or Major CV Events
in All Randomized Subjects
30
Pravastatin 40mg
25 (26.3%)
20
%
Atorvastatin 80mg
with 15 (22.4%)
Event
10
16% RR
5 (P =
0.005)
0
0 3 6 9 12 15 18 21 24 27 30
Months of Follow-up
Summary of PROVE-IT Results
In patients recently hospitalized within 10 days for an
acute coronary syndrome:
“Intensive” high-dose LDL-C lowering (median LDL-C 62
mg/dL) compared to “moderate” standard-dose lipid-lowering
therapy (median LDL-C 95 mg/dL) reduced the risk of all cause
mortality or major cardiac events by 16% (p=0.005)
Benefits emerged within 30 days post ACS with continued benefit
observed throughout the 2.5 years of follow-up
Benefits were consistent across all cardiovascular endpoints,
except stroke, and most clinical subgroups
Invasive vs Conservative
Strategies
Invasive vs Conservative Strategy
Clinical Trials
ISAR-
COOL
MATE VINO
Conservative Invasive
Strategy Favored No difference Strategy Favored
N=920 N=2,874 N=7,018
How Early is Early?
Secondary Prevention
Class I Indications
Aspirin
Beta-blockers: (all pts, slow titration with moderate to
severe failure
ACE-Inhibitors: CHF, EF<40%, HTN, DM
(All pts-Class IIa) ARB when intolerant to ACE.
(Class IIa as alternative to ACEI)
Aldosterone blockade: An ACEI, CHF with either
EF<40% or DM and if CrCl>30 ml/min and K<5.0
mEq/L
Statins
Standard Risk Factor Management
Long-Term Antithrombotic Therapy at Hospital
Discharge after UA/NSTEMI
New UA/NSTEMI
Patient Groups at
Discharge
ASA 75 to 162 mg/d indefinitely ASA 162 to 325 mg/d for at least 1 ASA 162 to 325 mg/d for at
(Class I, LOE: A) month, then 75 to 162 mg/d least 3 to 6 months, then 75 to
indefinitely (Class I, LOE: A) 162 mg/d indefinitely
& (Class I, LOE: A)
&
Clopidogrel 75 mg/d at least 1 &
Clopidogrel 75 mg/d for at least 1
month (Class I, LOE: A) and up
month and up to 1 year Clopidogrel 75 mg/d for at
to 1 year (Class I, LOE: B)
(Class I, LOE:B) least 1 year (Class I, LOE: B)
Indication for
Anticoagulation?
Yes No
Add: Warfarin (INR 2.0 to 2.5) Continue with dual antiplatelet
(Class IIb, LOE: B) therapy as above
Anderson JL, et al. J Am Coll Cardiol 2007;50:e1–e157, Figure 11. INR = international normalized ratio; LOE = level of evidence.
Secondary Prevention
Class III